Opin vísindi

COVID-19 related outcomes among individuals with neurodegenerative diseases : a cohort analysis in the UK biobank

COVID-19 related outcomes among individuals with neurodegenerative diseases : a cohort analysis in the UK biobank


Title: COVID-19 related outcomes among individuals with neurodegenerative diseases : a cohort analysis in the UK biobank
Author: Hu, Yihan
Yang, Huazhen
Hou, Can
Chen, Wenwen
Zhang, Hanyue
Ying, Zhiye
Hu, Yao
Sun, Yajing
Qu, Yuanyuan
Feychting, Maria
... 3 more authors Show all authors
Date: 2022-12
Language: English
Scope:
Department: Faculty of Medicine
Series: BMC Neurology; 22(1)
ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-021-02536-7
Subject: Hrörnunarsjúkdómar; COVID-19; Hóprannsóknir; Cohort study; COVID-19; Neurodegenerative diseases; UK biobank; Neurology (clinical)
URI: https://hdl.handle.net/20.500.11815/3049

Show full item record

Citation:

Hu , Y , Yang , H , Hou , C , Chen , W , Zhang , H , Ying , Z , Hu , Y , Sun , Y , Qu , Y , Feychting , M , Valdimarsdóttir , U A , Song , H & Fang , F 2022 , ' COVID-19 related outcomes among individuals with neurodegenerative diseases : a cohort analysis in the UK biobank ' , BMC Neurology , vol. 22 , no. 1 , 15 . https://doi.org/10.1186/s12883-021-02536-7

Abstract:

Background: An increased susceptibility to COVID-19 has been suggested for individuals with neurodegenerative diseases, but data are scarce from longitudinal studies. Methods: In this community-based cohort study, we included 96,275 participants of the UK Biobank who had available SARS-CoV-2 test results in Public Health England. Of these, 2617 had a clinical diagnosis of neurodegenerative diseases in the UK Biobank inpatient hospital data before the outbreak of COVID-19 (defined as January 31st, 2020), while the remaining participants constituted the reference group. We then followed both groups from January 31st, 2020 to June 14th, 2021 for ascertainment of COVID-19 outcomes, including any COVID-19, inpatient care for COVID-19, and COVID-19 related death. Logistic regression was applied to estimate the association between neurogenerative disease and risks of COVID-19 outcomes, adjusted for multiple confounders and somatic comorbidities. Results: We observed an elevated risk of COVID-19 outcomes among individuals with a neurodegenerative disease compared with the reference group, corresponding to a fully adjusted odds ratio of 2.47 (95%CI 2.25–2.71) for any COVID-19, 2.18 (95%CI 1.94–2.45) for inpatient COVID-19, and 3.67 (95%CI 3.11–4.34) for COVID-19 related death. Among individuals with a positive test result for SARS-CoV-2, individuals with neurodegenerative diseases had also a higher risk of COVID-19 related death than others (fully adjusted odds ratio 2.08; 95%CI 1.71–2.53). Conclusion: Among UK Biobank participants who received at least one test for SARS-CoV-2, a pre-existing diagnosis of neurodegenerative disease was associated with a subsequently increased risk of COVID-19, especially COVID-19 related death.

Description:

Publisher Copyright: © 2022, The Author(s). This work is supported by the National Natural Science Foundation of China (No. 81971262 to HS), West China Hospital COVID-19 Epidemic Science and Technology Project (No. HX-2019-nCoV-014 to HS), Sichuan University Emergency Grant (No. 2020scunCoVyingji10002 to HS), National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University (No. Z20201013 to HS), Project Grant form Science & Technology Department of Sichuan Providence (2020YFS0575 to HS), and NordForsk grant (105668 to UV and FF). The funding agencies did not have any role in the design of study, data collection, data analysis, interpretation or writing the manuscript.

Files in this item

This item appears in the following Collection(s)